Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00459056
Status:
COMPLETED
Last Update Posted:
2013-12-06
First Post:
2007-04-10
Brief Title:
The Vascular Effects of Carvedilol Controlled Release CR in Abdominally Obese Hypertensive Patients
Sponsor:
St Paul Heart Clinic
Organization:
St Paul Heart Clinic
Study Overview
Official Title:
The Vascular Effects of Carvedilol Controlle Release CR Lisinopril Versus Lisinopril Hydrochlorothiazide HCTZ in Abdominally Obese Hypertensive Patients
Status:
COMPLETED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the effects of two different combination therapies for high blood pressure on vascular health
Detailed Description:
Hydrochlorothiazide HCTZ has been a popular choice for the treatment of hypertension mainly due to its efficacy in lowering blood pressure safety and cost-effectiveness Similarly angiotensin converting enzyme inhibitors ACE-I because of their neutral to positive impact on glycemic control have been a popular choice for addressing hypertension in abdominally obese patients Furthermore the ACE-I drug class has been shown to improve vascular endothelial function and inflammation in addition to its blood pressure lowering effects
Conversely beta-adrenergic receptor blockers b-blockers have generally been avoided as first line anti-hypertensive therapy in pre-diabetic patients due to concerns about worsening glycemic control and potential hastening of progression to type 2 diabetes mellitus T2DM However recent data have shown that the 3rd generation b-blocker carvedilol does not negatively affect glucose metabolism and therefore may be a safe and effective choice for blood pressure control in these patients This neutral glycemic effect is likely due to the fact that carvedilol is a non-selective b-receptor antagonist blocks both b1 and b2 receptors with alpha1-receptor blocking properties In addition carvedilol possesses anti-oxidant properties and improves endothelial function potentially making it an attractive anti-hypertensive treatment strategy in patients with abdominal obesity
The combination of carvedilol and lisinopril may be especially effective in reducing blood pressure and may act synergistically to address the impaired vascular function and increased inflammation and oxidative stress present in patients with the metabolic syndrome phenotype Therefore the primary objective of the current study will be to evaluate the effects of carvedilol CR lisinopril compared to lisinopril HCTZ on vascular function in a head to head trial in abdominally obese hypertensive patients The secondary objective will be to compare the effects of these two anti-hypertensive therapies on plasma biomarkers of endothelial activation inflammation and oxidative stress in these patients
Conversely beta-adrenergic receptor blockers b-blockers have generally been avoided as first line anti-hypertensive therapy in pre-diabetic patients due to concerns about worsening glycemic control and potential hastening of progression to type 2 diabetes mellitus T2DM However recent data have shown that the 3rd generation b-blocker carvedilol does not negatively affect glucose metabolism and therefore may be a safe and effective choice for blood pressure control in these patients This neutral glycemic effect is likely due to the fact that carvedilol is a non-selective b-receptor antagonist blocks both b1 and b2 receptors with alpha1-receptor blocking properties In addition carvedilol possesses anti-oxidant properties and improves endothelial function potentially making it an attractive anti-hypertensive treatment strategy in patients with abdominal obesity
The combination of carvedilol and lisinopril may be especially effective in reducing blood pressure and may act synergistically to address the impaired vascular function and increased inflammation and oxidative stress present in patients with the metabolic syndrome phenotype Therefore the primary objective of the current study will be to evaluate the effects of carvedilol CR lisinopril compared to lisinopril HCTZ on vascular function in a head to head trial in abdominally obese hypertensive patients The secondary objective will be to compare the effects of these two anti-hypertensive therapies on plasma biomarkers of endothelial activation inflammation and oxidative stress in these patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None